Alien Investor Day – Health Tech

30 March 2023 - online

Time: 10:00 am - 11:30 am CET

We are thrilled to announce another event dedicated to connecting our network of selected companies with investors.

This exclusive event will focus on Health Tech innovations and it will bring together 5 selected top-class Israeli companies that have been recently awarded a € 2.5 M non dilutive grant from the European Commission (through the EIC Accelerator funding scheme) and are looking to raise further funding, between € 2 - 15 M.

During this 1 hour 30 minutes e-pitching event, the following startups will present their innovative business cases in front of a selected panel of Investors.

Zygofix, Israel

Over 1M spinal fusion procedures performed annually worldwide. Current spinal fusion procedures are highly invasive: they are based on building screw-bridges, connected by metal rods stabilizing motion between vertebrae. There are no effective treatments in the market that substitute the current invasive implants. zLOCK is a small implant that resolves spinal fusion by eliminating the need for screws and rods. zLOCK minimizes the invasiveness of procedures through a percutaneous approach, where only a small skin incision is required for implant placement, making it suitable for outpatient procedures. zLOCK can revolutionize spinal fusion standard clinical practice and the market. The implant value propositions have been confirmed in a first in human trial. With the EIC Accelerator project, ZygoFix will complete the necessary upgrades and clinical validation activities, achieve CE-mark and accelerate the time-to- market of zLOCK.

EzMems, Israel

Today's demanding medical treatment, pharmaceutical production and distribution operations require careful control of patients and process conditions. This includes tasks like accurate feedback of the respiratory status of the patient, detecting occlusion during infusions, process monitoring during cell culture, purification, or drug product formulation etc. The key enabling technology to digitize such tasks is to have cost efficient multi-sensing capabilities at the most critical edge point of the process. The currently used medical/pharma systems lack sensing capabilities as sensors are expensive to integrate, generally sense only one physical parameter, are bulky, needing electrical power source, and cannot provide wireless power transmission and multisensing at the edge. Multi-sensing at the edge offers new opportunities to develop intelligent monitoring network in hospitals and pharma manufacturing to provide fast and accurate responses saving costs also lowering the environmental footprint at the time of sensors manufacturing.

Nanovation, Israel

Disease monitoring is key for patients with chronic respiratory conditions. Chronic Obstructive Pulmonary Diseases (COPD) is a long-term condition that causes inflammation in the lungs, making breathing difficult. It is a large growing public health problem, expected to become one of the leading causes of death by 2030. Nevertheless, COPD patients lack of a constant and accurate monitoring throughout their disease. This can result in non-adequate therapeutic measures, which can often lead to potential serious effects on patient’s status and high costs for healthcare systems. SenseGuard is a reliable solution for monitoring of patients with respiratory diseases, including COPD, based on a unique nanosensor-based technology. It is an innovative wireless wearable device that enables continuous and non-invasive monitoring of lung functions derived from patients' tidal (normal) breathing. NanoVation is an Israeli SME, founded in 2014, which develops and integrates nanomaterial-based sensors for medical applications and general purposes and is run by an experienced and multi-disciplinary team of 12 people. During the proposed Phase 2 project, NanoVation will finalise the development of the SenseGuard device and validate its efficacy and safety in dedicated clinical studies.

Trisol Medical, Israel

In Europe, an estimated 6.5M people are affected by heart valve disease (HVD) each year. Tricuspid regurgitation (TR) is a HVD which occurs when the tricuspid valve fails to close properly, causing blood to flow backward into the right atrium. Many cases of TR are accompanied by Right Ventricle (RV) Dysfunction. The gold standard methods for tricuspid valve diseases are standard open-heart surgery and transcatheter valve replacement. However, high-risk interventions require long recovery time long in-hospital stays and have significant hospital mortality (more than 10%). Due to the high risk related to the surgical procedure, most of the patients cannot be treated. As such, there is a significant unmet clinical need for a transcatheter solution to TR. Trisol is introducing the Trisol System, a transcatheter tricuspid valve replacement system for treating severe TR and preventing RV dysfunction. The Trisol valve is constructed out of nitinol frame with specially designed sail-like leaflet. A flexible delivery system is used to position the valve into the heart with support arms anchoring to the tricuspid physiological site. The Trisol System allows cardiologists to perform a quick and safe implant procedure (30 minutes compared to 2-4 hours of standard surgery) thus increasing the number of treated population and reducing in-hospital and recovery time. Moreover, it will increase heart performance and reduce the risk of mortality typical of open-heart surgeries. The EIC Accelerator project will enable Trisol to scale-up production, perform validation and verification activities including a preclinical study; and validate the safety and efficacy of the Trisol System in the First-In-Human and CE mark clinical trial.

Yonalink,Israel

YonaLink (YL) is an Israeli company established in 2018 with the mission to disrupt the €46B clinical research market by connecting the world of Prospective Clinical Trial Data. To this end, YL is developing the YL System, a platform to migrate clinical research data saved in the patient health records, from medical centres to research database(s) in an automated, secure, validated, trusted and error-free way. The company has secured over €1.8M in the development of the YL System, reaching TRL 7 with pilot trials implementing it at Soroka MC (Clalit Health Insurance leading hospital) and in Sheba MC. The trials have confirmed the accuracy in migrating patients’ de-identified data from the EHR to the trial DB. EIC support will allow YL to finish optimization and validate the YL System in a multicentre–multinational pilot, demonstrating the advantage of automatic data transfer from EHR to the prospective trial database to all the clinical trial stakeholders in the EU.

Detailed Agenda

For any information or registratios to this event, please contact communications@alientt.com.